A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

Trial ID: NCT06758544

Interventional - Phase 1/2 - Recruiting

This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.

Conditions

• Pancreatic Cancer

Interventions

• Oncolytic virus VRT106
• Chemotherapy

Eligibility

Inclusion criteria

• 1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.
• 2. Males and females at 18-75 years of age, inclusive, at the Screening Visit.
• 3. Have a clinical diagnosis of pancreatic cancer.
• 4. An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
• 5. Expected survival time of≥6 months.
• 6. No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions.

Exclusion criteria

• 1. Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer.
• 2. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.
• 3. Immunocompromised patients.
• 4. Known alcohol or drug dependency.
• 5. Women who are pregnant or breastfeeding.

Sponsor

Guangdong Provincial People's Hospital, Guangzhou Virotech Pharmaceutical Co., Ltd.

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows